https://www.selleckchem.com/products/h2dcfda.html
Antifungal prophylaxis during induction for acute myeloid leukemia (AML) varies according to local rates of invasive fungal infections (IFIs). We evaluated fluconazole prophylaxis and no antifungal prophylaxis, as a natural interrupted time-series study to assess survival and infection complications. We identified patients with AML≥ 18 years old undergoing induction chemotherapy during 2 time periods period 1, fluconazole prophylaxis from August 1, 2013 to September 30, 2015, and period 2, no prophylaxis from October 1, 2015 to December
Like
Comment
Share
